Elsevier Global Medical News/Oncology Stat interviews Dr. Hyman Muss on the CALGB/CTSU 49907 trial. The study compared the oral agent capecitabine with standard chemo in women over age 65 with early-stage breast cancer. Interviewer: Mary Ellen Schneider, EGMN
All Comments